[{"id":"23e6ea0a-e3e2-4fd3-b084-8332cba9dab5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00455559","created_at":"2021-01-18T01:36:55.198Z","updated_at":"2024-07-02T16:37:13.730Z","phase":"Phase 2","brief_title":"Ph II Study of Perifosine Plus Gleevec for Patients With GIST","source_id_and_acronym":"NCT00455559","lead_sponsor":"AEterna Zentaris","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • perifosine (D21266)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 10/01/2011","study_completion_date":" 10/01/2011","last_update_posted":"2018-02-22"},{"id":"e6547ba9-4091-4337-b873-4351cecd30c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00498966","created_at":"2021-01-18T01:47:08.971Z","updated_at":"2024-07-02T16:37:14.208Z","phase":"Phase 2","brief_title":"Ph II Study of Perifosine for Patients With Carcinoma of the Kidney","source_id_and_acronym":"NCT00498966","lead_sponsor":"AEterna Zentaris","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e perifosine (D21266)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2007","start_date":" 07/01/2007","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 10/01/2011","study_completion_date":" 10/01/2011","last_update_posted":"2018-02-05"}]